Home / Business News (page 3)

Business News

Merck Exercises Option for Global Rights to NGM Bio’s Investigational NGM313 for the Treatment of NASH and Type 2 Diabetes

KENILWORTH, N.J., and SOUTH SAN FRANCISCO, C.A. Jan. 3, 2019 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, and NGM Biopharmaceuticals, Inc. (NGM) today announced that Merck has exercised its option to license NGM313, an investigational monoclonal antibody agonist of the β-Klotho/FGFR1c receptor complex that …

Read More »

Bristol-Myers Squibb to Acquire Celgene for $74 Billion

NEW YORK & SUMMIT, N.J.,–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE:BMY) and Celgene Corporation (NASDAQ:CELG) today announced that they have entered into a definitive merger agreement under which Bristol-Myers Squibb will acquire Celgene in a cash and stock transaction with an equity value of approximately $74 billion. Under the terms of the …

Read More »

Personal Genome Diagnostics Collaborates with Merck on Clinical Trial Evaluating Response to Dual Biomarker Directed Precision Oncology Combination Therapy

BALTIMORE–(BUSINESS WIRE)–Personal Genome Diagnostics Inc. (PGDx), a leader in cancer genomics, today reported that its 500+ gene pan-cancer tumor profiling tissue assay is being used in Merck’s Phase 2 precision oncology KeyImPaCT study of biomarker-directed, pembrolizumab-based combination therapy for advanced non-small-cell lung cancer (NSCLC) (KEYNOTE-495). This study will investigate the …

Read More »

Takeda Announces Multiple Cell Therapy Collaborations to Advance the Company’s Novel Immuno-Oncology Portfolio

CAMBRIDGE, Mass. & OSAKA, Japan–(BUSINESS WIRE)–Takeda Pharmaceutical Company Limited (“Takeda”) (TSE: 4502) today announced new research collaborations in immuno-oncology (I-O), an area of key strategic focus for the company. Through these collaborations, Takeda seeks to accelerate the discovery of next-generation cancer immunotherapies, including novel cell therapy approaches that may provide …

Read More »

Horizon Pharma and HemoShear Therapeutics Enter Exclusive Drug Discovery Collaboration in Gout

DUBLIN & CHARLOTTESVILLE, Va.–(BUSINESS WIRE)–Horizon Pharma plc (Nasdaq: HZNP) and HemoShear Therapeutics, LLC, a privately held biotechnology company, today announced a collaboration to discover and develop novel therapeutics for gout. “As we continue to grow our pipeline, we are committed to addressing unmet treatment needs for people with gout as …

Read More »

Vertex and Arbor Partner to Discover Novel Proteins to Advance Discovery of Gene-Editing Therapies for Cystic Fibrosis

BOSTON & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) and Arbor Biotechnologies (Arbor) today announced that the two companies have entered into a strategic research collaboration focused on the discovery of novel proteins including DNA endonucleases to advance the development of new gene-editing therapies for cystic fibrosis and four other diseases …

Read More »

Veracyte and Johnson & Johnson Innovation to Collaborate for Novel Diagnostic Tests to Detect Lung Cancer at its Earliest Stages

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Veracyte, Inc. (“Veracyte”) (Nasdaq: VCYT) announced today that it has entered into a long-term strategic collaboration with Johnson & Johnson Innovation LLC* and the Lung Cancer Initiative at Johnson & Johnson to advance the development and commercialization of novel diagnostic tests to detect lung cancer at its earliest …

Read More »

Medical Device Developer EnClear Therapies Spins Out of QurAlis with a Focus on Neurological Diseases

CAMBRIDGE, Mass.–(BUSINESS WIRE)–EnClear Therapies, a medical device company focused on developing therapeutic systems that continuously clear toxic proteins from cerebrospinal fluids (CSF) for the treatment of neurological diseases, today announced that it has spun-out from QurAlis Corporation, a biotech company focused on developing precision therapeutics for ALS and other neurological diseases. EnClear’s mission …

Read More »

Boston Scientific Acquires Remaining Shares of Millipede, Expanding its Heart Portfolio

MARLBOROUGH, Mass., Dec. 27, 2018 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) today announced it exercised its option to acquire the remaining shares of Millipede, Inc, a privately-held company in Santa Rosa, Calif., upon its recent successful completion of a first-in-human clinical study. The acquisition will expand the Boston Scientific …

Read More »

Cigna Completes Combination with Express Scripts, Establishing a Blueprint to Transform the Health Care System

BLOOMFIELD, Conn.–(BUSINESS WIRE)–Cigna Corporation (NYSE: CI), a leading global health service company, has successfully completed its combination with Express Scripts Holding Company (“Express Scripts”) effective December 20, 2018. Consistent with its commitment to support local communities and improve societal health, Cigna also announced an incremental investment of $200 million to …

Read More »